Literature DB >> 27278789

The roles of microRNAs in the progression of castration-resistant prostate cancer.

Satoko Kojima1, Yusuke Goto2, Yukio Naya1.   

Abstract

Prostate cancer (PCa) is one of the leading causes of cancer-related death in men. PCa is androgen-dependent, and androgen-deprivation therapy is effective for first-line hormonal treatment, but the androgen-independent phenotype of PCa eventually develops, which is difficult to treat and has no effective cure. Recently, microRNAs have been discovered to have important roles in the initiation and progression of PCa, suggesting their use in diagnosis, predicting prognosis and development of treatment for castration-resistant PCa (CRPC). Understanding the networks of microRNAs and their target genes is necessary to ascertain their roles and importance in the development and progression of PCa. This review summarizes the current knowledge about microRNAs regulating PCa progression and elucidates the mechanism of progression to CRPC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27278789     DOI: 10.1038/jhg.2016.69

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  130 in total

1.  APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

Authors:  Jack Groskopf; Sheila M J Aubin; Ina Lim Deras; Amy Blase; Sharon Bodrug; Craig Clark; Steven Brentano; Jeannette Mathis; Jimmykim Pham; Troels Meyer; Michelle Cass; Petrea Hodge; Maria Luz Macairan; Leonard S Marks; Harry Rittenhouse
Journal:  Clin Chem       Date:  2006-04-20       Impact factor: 8.327

Review 2.  Functional significance of aberrantly expressed microRNAs in prostate cancer.

Authors:  Yusuke Goto; Akira Kurozumi; Hideki Enokida; Tomohiko Ichikawa; Naohiko Seki
Journal:  Int J Urol       Date:  2015-01-20       Impact factor: 3.369

3.  MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening.

Authors:  Sven Wach; Elke Nolte; Jaroslaw Szczyrba; Robert Stöhr; Arndt Hartmann; Torben Ørntoft; Lars Dyrskjøt; Elke Eltze; Wolf Wieland; Bastian Keck; Arif B Ekici; Friedrich Grässer; Bernd Wullich
Journal:  Int J Cancer       Date:  2011-05-09       Impact factor: 7.396

4.  The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer.

Authors:  Satoko Kojima; Hideki Enokida; Hirofumi Yoshino; Toshihiko Itesako; Takeshi Chiyomaru; Takashi Kinoshita; Miki Fuse; Rika Nishikawa; Yusuke Goto; Yukio Naya; Masayuki Nakagawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2013-11-28       Impact factor: 3.172

5.  The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer.

Authors:  Martin Hart; Sven Wach; Elke Nolte; Jaroslaw Szczyrba; Roopika Menon; Helge Taubert; Arndt Hartmann; Robert Stoehr; Wolf Wieland; Friedrich A Grässer; Bernd Wullich
Journal:  FEBS J       Date:  2013-04-08       Impact factor: 5.542

6.  miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells.

Authors:  Dejuan Kong; Yiwei Li; Zhiwei Wang; Sanjeev Banerjee; Aamir Ahmad; Hyeong-Reh Choi Kim; Fazlul H Sarkar
Journal:  Stem Cells       Date:  2009-08       Impact factor: 6.277

7.  A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells.

Authors:  Miao Ding; Biaoyang Lin; Tao Li; Yuanyuan Liu; Yuhua Li; Xiaoyu Zhou; Maohua Miao; Jinfa Gu; Hongjie Pan; Fen Yang; Tianqi Li; Xin Yuan Liu; Runsheng Li
Journal:  Oncotarget       Date:  2015-04-10

8.  miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice.

Authors:  Cyrielle Clapé; Vanessa Fritz; Corinne Henriquet; Florence Apparailly; Pedro Luis Fernandez; François Iborra; Christophe Avancès; Martin Villalba; Stéphane Culine; Lluis Fajas
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

9.  The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.

Authors:  M Avgeris; K Stravodimos; E G Fragoulis; A Scorilas
Journal:  Br J Cancer       Date:  2013-05-23       Impact factor: 7.640

10.  Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.

Authors:  Heather H Cheng; Patrick S Mitchell; Evan M Kroh; Alexander E Dowell; Lisly Chéry; Javed Siddiqui; Peter S Nelson; Robert L Vessella; Beatrice S Knudsen; Arul M Chinnaiyan; Kenneth J Pienta; Colm Morrissey; Muneesh Tewari
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

View more
  15 in total

1.  MiR-133a-5p inhibits androgen receptor (AR)-induced proliferation in prostate cancer cells via targeting FUsed in Sarcoma (FUS) and AR.

Authors:  Long Zheng; Ye Kang; Lei Zhang; Wen Zou
Journal:  Cancer Biol Ther       Date:  2019-11-17       Impact factor: 4.742

2.  Bioinformatics Prediction and Analysis of MicroRNAs and Their Targets as Biomarkers for Prostate Cancer: A Preliminary Study.

Authors:  Chipampe Patricia Lombe; Mervin Meyer; Ashley Pretorius
Journal:  Mol Biotechnol       Date:  2021-10-19       Impact factor: 2.695

3.  Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis.

Authors:  Yasutaka Yamada; Rika Nishikawa; Mayuko Kato; Atsushi Okato; Takayuki Arai; Satoko Kojima; Kazuto Yamazaki; Yukio Naya; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2017-12-01       Impact factor: 3.172

Review 4.  Exploiting Epigenetic Alterations in Prostate Cancer.

Authors:  Simon J Baumgart; Bernard Haendler
Journal:  Int J Mol Sci       Date:  2017-05-09       Impact factor: 5.923

Review 5.  Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.

Authors:  Kristine M Wadosky; Shahriar Koochekpour
Journal:  Oncotarget       Date:  2016-09-27

6.  The diagnostic effect of serum miR-196b as biomarker in colorectal cancer.

Authors:  Chunjie Xu; Lei Gu
Journal:  Biomed Rep       Date:  2016-11-18

7.  Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells.

Authors:  Dominique Z Jones; M Lee Schmidt; Suman Suman; Katharine R Hobbing; Shirish S Barve; Leila Gobejishvili; Guy Brock; Carolyn M Klinge; Shesh N Rai; Jong Park; Geoffrey J Clark; Rajesh Agarwal; LaCreis R Kidd
Journal:  BMC Cancer       Date:  2018-04-13       Impact factor: 4.430

Review 8.  Epithelial-mesenchymal transition in prostate cancer: an overview.

Authors:  Micaela Montanari; Sabrina Rossetti; Carla Cavaliere; Carmine D'Aniello; Maria Gabriella Malzone; Daniela Vanacore; Rossella Di Franco; Elvira La Mantia; Gelsomina Iovane; Raffaele Piscitelli; Raffaele Muscariello; Massimiliano Berretta; Sisto Perdonà; Paolo Muto; Gerardo Botti; Attilio Antonio Montano Bianchi; Bianca Maria Veneziani; Gaetano Facchini
Journal:  Oncotarget       Date:  2017-05-23

Review 9.  Molecular and cellular mechanisms of castration resistant prostate cancer.

Authors:  Yiqiao Huang; Xianhan Jiang; Xue Liang; Ganggang Jiang
Journal:  Oncol Lett       Date:  2018-02-27       Impact factor: 2.967

Review 10.  Coordinated AR and microRNA regulation in prostate cancer.

Authors:  Ieva Eringyte; Joanna N Zamarbide Losada; Sue M Powell; Charlotte L Bevan; Claire E Fletcher
Journal:  Asian J Urol       Date:  2020-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.